Cargando…

Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3

BACKGROUND: The phase III ATTRACTION-3 study showed that second-line nivolumab monotherapy for advanced esophageal squamous cell carcinoma prolonged overall survival (OS) but did not improve progression-free survival (PFS). Subsequent systemic therapy after discontinuing nivolumab may affect these o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chin, Keisho, Yamamoto, Shun, Takahashi, Masanobu, Kadowaki, Shigenori, Kubota, Yutaro, Amanuma, Yusuke, Okada, Morihito, Kanda, Mitsuro, Kimura, Yasue, Nogi, Yuhiko, Arimitsu, Yuko, Kitagawa, Yuko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024664/ https://www.ncbi.nlm.nih.gov/pubmed/36564602 http://dx.doi.org/10.1007/s10388-022-00972-z

Ejemplares similares

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)
por: Takahashi, Masanobu, et al.
Publicado: (2020)

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
por: Okada, Morihito, et al.
Publicado: (2022)

Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma
por: Ohsawa, Manato, et al.
Publicado: (2023)

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)
por: Kato, Ken, et al.
Publicado: (2022)

Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer
por: Imai, Hiroo, et al.
Publicado: (2018)

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
por: Boku, Narikazu, et al.
Publicado: (2021)

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)
por: Satoh, Taroh, et al.
Publicado: (2021)

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2018)

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2020)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Successful treatment of gastric cancer after complete response of lung cancer by nivolumab: a case report
por: Endo, Shunji, et al.
Publicado: (2020)

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2023)

Assessment of Age-related Decline of Immunological Function and Possible Methods for Immunological Restoration in Elderly
por: Hirokawa, Katsuiku, et al.
Publicado: (2008)

P-gp and taxanes
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2014)

Mechanisms of Taxane Resistance
por: Maloney, Sara M., et al.
Publicado: (2020)

Job Attractiveness and Job Satisfaction of Dental Hygienists: From Japanese Dental Hygienists’ Survey 2019
por: Ohara, Yuki, et al.
Publicado: (2021)

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan
por: Aoki, Masahiko, et al.
Publicado: (2022)

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
por: Kang, Yoon-Koo, et al.
Publicado: (2021)

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer
por: Iikura, Yusuke, et al.
Publicado: (2022)

Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports
por: Takimoto, Rishu, et al.
Publicado: (2021)

Predictive value of integrated (18)F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer
por: Umeda, Yukihiro, et al.
Publicado: (2020)

Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge
por: Anoop, T M, et al.
Publicado: (2022)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
por: Kianersi, Shirin, et al.
Publicado: (2023)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Late Onset of Cardiac Metastasis of a Melanoma following Nivolumab Immunotherapy
por: Nakamura, Kenta, et al.
Publicado: (2022)

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer
por: Kato, Ken, et al.
Publicado: (2020)

Taxane-Induced Peripheral Neurotoxicity
por: Velasco, Roser, et al.
Publicado: (2015)

Sex Differences in Taxane Toxicities
por: Chmielewski, Nicole N., et al.
Publicado: (2022)

To Discover the Efficient and Novel Drug Targets in Human Cancers Using CRISPR/Cas Screening and Databases
por: Onishi, Iichiroh, et al.
Publicado: (2021)

Preoperative predictors of postoperative complications after gastric cancer resection
por: Kanda, Mitsuro
Publicado: (2019)

Correction to: Preoperative predictors of postoperative complications after gastric cancer resection
por: Kanda, Mitsuro
Publicado: (2020)

Effective treatment of gallbladder neuroendocrine carcinoma with nivolumab
por: Kanda, Shinichiro, et al.
Publicado: (2023)

FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
por: Higuchi, Mitsunori, et al.
Publicado: (2016)

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan
por: Kanbayashi, Yuko, et al.
Publicado: (2023)

Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review
por: Gamulin, Marija, et al.
Publicado: (2020)

Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review
por: Ota, Shuji, et al.
Publicado: (2019)

Docetaxel: an alternative taxane in ovarian cancer
por: Katsumata, N
Publicado: (2003)

Disposition Kinetics of Taxanes in Peritoneal Dissemination
por: Miyamoto, Ken'ichi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sp5m5mgejchrg8hpad69jsu3an